🏛️ Verified NIH Record • Updated 2025-11-04

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) (NCT04245839)

A Phase 2, Open-label, Single Arm, Multicohort, Multicenter Trial to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Celgene

🩺 Plain-English Summary (8th-Grade Level)

This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/r FL or MZL. The study will be conducted in compliance with the International Council on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements. This study is divided into three periods: * Pretreatment, which consists of screening assessments, leukapheresis and the Pretreatment evaluation; * Treatment, which starts with the administration of lymphodepleting (LD) chemotherapy and continues through JCAR017 administration at Day 1 with follow-up through Day 29; * Posttreatment, which includes follow-up assessments for disease status and safety for 5 years.

Who can join: Review the eligibility criteria below.

Location: Local Institution - 111 — Santa Monica, California

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (49 Sites)

Showing the first 25 of 49 sites.

  • Local Institution - 111 — Santa Monica, California
  • Local Institution - 107 — Aurora, Colorado
  • Local Institution - 105 — New Haven, Connecticut
  • Local Institution - 103 — Chicago, Illinois
  • Local Institution - 109 — Niles, Illinois
  • Local Institution - 122 — Iowa City, Iowa
  • Local Institution - 124 — Wichita, Kansas
  • Local Institution - 102 — Baltimore, Maryland
  • Local Institution - 100 — Boston, Massachusetts
  • Local Institution - 101 — Boston, Massachusetts
  • Local Institution - 127 — Detroit, Michigan
  • Local Institution - 123 — Morristown, New Jersey
  • Local Institution - 116 — New York, New York
  • Local Institution - 110 — Charlotte, North Carolina
  • Local Institution - 112 — Cleveland, Ohio
  • Local Institution - 114 — Portland, Oregon
  • Local Institution - 117 — Philadelphia, Pennsylvania
  • Local Institution - 113 — Sioux Falls, South Dakota
  • Local Institution - 121 — Dallas, Texas
  • Local Institution - 104 — Houston, Texas
  • Local Institution - 119 — Houston, Texas
  • Local Institution - 115 — Charlottesville, Virginia
  • Local Institution - 108 — Seattle, Washington
  • Local Institution - 450 — Vienna,
  • Local Institution - 150 — Toronto, Ontario

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Lymphoma, Non-Hodgkin

Explore by condition: All Lymphoma, Non-Hodgkin clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Review the official NIH record below to find the coordinating site.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗